You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CPD

The Nonmetastatic Castration-Resistant Prostate Cancer Enigma: Who Are These Patients, and Why Is it Important to Identify and Treat?

  • Authors: Heather Payne, MBBS, FRCP, FRCR
  • CPD Released: 12/8/2021; Reviewed and Renewed: 11/8/2021
  • Valid for credit through: 12/8/2022
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.25 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of oncologists, urologists, pathologists, primary care physicians, and other members of the oncology care team treating patients with prostate cancer in the United Kingdom.

The goal of this activity is to define the need to identify patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and optimal approaches for treatment of this group of patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Identification of patients with nmCRPC
    • Importance of treatment for nmCRPC


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Heather Payne, MBBS, FRCP, FRCR

    Consultant in Clinical Oncology
    University College Hospital
    London, United Kingdom

    Disclosures

    Disclosure: Heather Payne, MBBS, FRCP, FRCR, has the following relevant financial relationships:
    Advisor or consultant for: AAA; AstraZeneca; Astellas; Bayer; Ferring; Janssen; Novartis
    Speaker or a member of a speakers bureau for: AAA; AstraZeneca; Astellas; Bayer; Ferring; Janssen; Novartis
    Grants for clinical research from: Astellas; Janssen

Editors

  • Deborah Grainger, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Deborah Grainger, PhD, has disclosed no relevant financial relationships.

  • Tristin Abair, PhD

    Senior Medical Writer, WebMD Global, LLC

    Disclosures

    Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

The Nonmetastatic Castration-Resistant Prostate Cancer Enigma: Who Are These Patients, and Why Is it Important to Identify and Treat?

Authors: Heather Payne, MBBS, FRCP, FRCRFaculty and Disclosures

CPD Released: 12/8/2021; Reviewed and Renewed: 11/8/2021

Valid for credit through: 12/8/2022

processing....

Assessment Survey

Before you begin, please answer the questions in this brief survey.